Dr. Liz Berry-Kravis and Tetra Therapeutics published their BPN14770 trial results in Nature Medicine today (April 29, 2021). You all know Dr. Berry-Kravis, and the name Tetra Therapeutics may be familiar to you — they presented at our 2020 NFXF International Fragile X Conference Virtual Series.

Here we summarize the article and explain why this matters to you and any next steps.

Learn about the phases of a clinical program and other research information by downloading our free Research 101: The Ultimate Guide for All Families Living with Fragile X ebook.

If you’re feeling inspired by the participants from this trial and their dedication to being an active part of finding treatments for Fragile X, check out current research opportunities on our MyFXResearch portal.

Authors: Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Lauren E. Ethridge, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, and Mark E. Gurney


Background, Methods & Results

Tetra Therapeutics initiated a Phase II clinical trial in Fragile X syndrome with the help of Principle Investigator Dr. Elizabeth Berry-Kravis. The goal of this study was to determine if a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral outcomes in patients with Fragile X syndrome (FXS), and looked at 30 men between the ages of 18 and 41 with full mutation FXS (> 200 CGG repeats).

This was a randomized, double-blind, placebo-controlled, two-period crossover study. This means that each of the 30 participants were randomly assigned to either treatment or placebo (randomized), neither the study team nor the participant knew what they were taking (double-blind), and all participants had a period when they were taking placebo and a period when they were on the study drug (two-period crossover study). Participants took either two doses of the study drug BPN14770 or two doses of placebo every day over 24 weeks.

Because this was a Phase II trial, the primary endpoint was evaluating the safety and tolerability of the study drug. Tetra also indicated exploratory secondary endpoints of cognitive performance, caregiver rating scales, and physician rating scales.

The trial met its primary endpoint of the study drug being safe and well-tolerated. All 30 participants completed the entire study. There were no meaningful differences in side effects between participants taking the study drug and participants taking placebo. The most commonly reported side effects were vomiting and upper respiratory infections, both of which were reported in participants taking the study drug and those in the placebo group.

The trial was also successful with their exploratory secondary endpoints. There was a statistically significant improvement in language that was assessed directly by using different tests within the NIH Toolbox and by the parent/caregiver reported Visual Analog Scale (VAS). The other clinical assessments administered throughout the trial showed a positive trend for improvement also.

Why It Matters

There are currently no FDA-approved treatments specifically for FXS. While many individuals with FXS take medications that treatment certain symptoms of FXS, families living with FXS share that there is much room for improvement. During the NFXF-led PFDD meeting, some parents and caregivers expressed the importance of cognition, daily functioning, and independence, especially for their adults with FXS. Improvement in language and communication would be particularly beneficial for individuals with FXS as indicated by the FX community.

BPN14770 was found to be well-tolerated and safe in the Phase II trials and met key secondary endpoints measuring cognition and daily functioning measured by the NIH Toolbox and VAS. These results mean that BPN14770 can move into Phase III trials. Phase III trials are important because these trials confirm the safety and effectiveness of the study drug. If the endpoints are met and the drug continues to be safe and effective, BPN14770 could be a candidate for FDA approval.

Next Steps

Tetra Therapeutics is hard at work designing their Phase III trials of BPN14770. Keep your eyes peeled for their next trial. NFXF will make sure you are aware of when the trial opens for enrollment (if you’re not already on our email list, subscribe now). This is part of the standard pathway to approval for any drug or device.

Acknowledgements: The authors wish to thank the patients and their families for participating in the clinical trial.

Funding: Direct clinical costs were funded by the FRAXA Research Foundation. Access to and training on the NIH Toolbox Cognitive Battery was obtained in association with work on RO1 HD076189 (E.M.B.K.). Tetra Therapeutics provided drug product and funded trial administration and independent data analysis.

Author Hilary Rosselot

Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!

more research results

Emotion Dysregulation in Fragile X Syndrome

Jan 19, 2024|

By Mya Jones Authors:  Rebecca C Shaffer, Debra L Reisinger, Lauren M Schmitt, Martine Lamy, Kelli C Dominick, Elizabeth G Smith, Marika C Coffman, Anna J Esbensen Summary: A large portion of individuals with Fragile X Syndrome (FXS) experience the inability to change how strongly they feel an emotional experience or how they respond to the experience, referred to as emotion dysregulation. Cincinnati Children’s Fragile X Center team reviewed the surrounding and relevant research conducted [...]